Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Artia Global Partners LP

Artia Global Partners LP grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 136.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 293,851 shares of the company's stock after acquiring an additional 169,411 shares during the quarter. Protagonist Therapeutics comprises approximately 4.1% of Artia Global Partners LP's portfolio, making the stock its 12th biggest holding. Artia Global Partners LP owned approximately 0.49% of Protagonist Therapeutics worth $11,343,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in PTGX. Boothbay Fund Management LLC acquired a new position in Protagonist Therapeutics in the 4th quarter valued at $779,000. New Vernon Capital Holdings II LLC acquired a new position in shares of Protagonist Therapeutics during the 4th quarter valued at about $118,000. Two Sigma Securities LLC purchased a new position in shares of Protagonist Therapeutics during the 4th quarter worth about $212,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Protagonist Therapeutics by 6.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock worth $53,758,000 after acquiring an additional 83,185 shares during the period. Finally, Eversept Partners LP boosted its position in shares of Protagonist Therapeutics by 52.5% in the fourth quarter. Eversept Partners LP now owns 678,787 shares of the company's stock worth $26,201,000 after acquiring an additional 233,583 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX traded up $0.77 during mid-day trading on Friday, hitting $45.76. 312,440 shares of the company traded hands, compared to its average volume of 858,442. The firm's 50 day simple moving average is $46.16 and its 200 day simple moving average is $42.86. The firm has a market cap of $2.81 billion, a P/E ratio of 17.20 and a beta of 2.30. Protagonist Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PTGX. Truist Financial increased their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. BMO Capital Markets increased their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. JMP Securities reissued a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a report on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, February 24th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the transaction, the chief executive officer now owns 540,260 shares of the company's stock, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Asif Ali sold 24,903 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the transaction, the chief financial officer now owns 62,821 shares in the company, valued at approximately $3,689,477.33. The trade was a 28.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,532 shares of company stock valued at $3,665,786. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.